PCSK9 promotes atherosclerosis progression through the FOXO3a autophagy signaling pathway

• by Yuanjia Shi, Jing Zhang, Lina Dai, Jie Chen, Shijia Geng, Yan Niu, Chongyang Dong, Chenlei Li, Rujin Liu, Ningxia Zhao, Xiaomeng Wang, Zhanfeng Gao, Xi Yang, Shang Gao

• June 15, 2026

FDA Approves Low-Dose Macrocyclic Contrast Agent for MRI

The macrocyclic gadolinium-based contrast agent has a recommended dose of 0.01 mmol/kg actual body weight.

• by Kathryn Wighton

• June 15, 2026

• 3 min

Single-catheter radiofrequency pulmonary vein isolation for atrial fibrillation: a comparative evaluation

• by Alessio Falasca Zamponi, Fariborz Tabrizi, Anders Englund, Sergej Scheel, Jens Olson, Ivar Skoger, Christian Basile, Raffaele Scorza

• June 15, 2026

ACP Suggests First-Line Obesity Drugs

Semaglutide and tirzepatide had the greatest net benefit among evaluated treatments, the committee concluded.

• by Kathryn Wighton

• June 16, 2026

• 5 min